Ocular Therapeutix (OCUL) Competitors $11.92 +0.34 (+2.94%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.92 -0.01 (-0.04%) As of 08/1/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OCUL vs. RGC, RVMD, GRFS, TGTX, NUVL, RYTM, CRSP, AXSM, TLX, and LNTHShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Ocular Therapeutix vs. Its Competitors Regencell Bioscience Revolution Medicines Grifols TG Therapeutics Nuvalent Rhythm Pharmaceuticals CRISPR Therapeutics Axsome Therapeutics Telix Pharmaceuticals Lantheus Ocular Therapeutix (NASDAQ:OCUL) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability. Does the media prefer OCUL or RGC? In the previous week, Ocular Therapeutix had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 3 mentions for Ocular Therapeutix and 1 mentions for Regencell Bioscience. Ocular Therapeutix's average media sentiment score of 0.46 beat Regencell Bioscience's score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OCUL or RGC more profitable? Regencell Bioscience has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -323.09%. Regencell Bioscience's return on equity of 0.00% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-323.09% -59.92% -41.98% Regencell Bioscience N/A N/A N/A Do analysts recommend OCUL or RGC? Ocular Therapeutix currently has a consensus target price of $17.33, indicating a potential upside of 45.41%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, OCUL or RGC? Ocular Therapeutix has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Regencell Bioscience has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Do institutionals and insiders believe in OCUL or RGC? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable valuation & earnings, OCUL or RGC? Regencell Bioscience has lower revenue, but higher earnings than Ocular Therapeutix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M29.80-$193.51M-$1.15-10.37Regencell BioscienceN/AN/A-$4.30MN/AN/A SummaryOcular Therapeutix beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks. Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.84B$2.46B$5.49B$9.54BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-10.378.9728.8323.83Price / Sales29.80437.65372.0766.02Price / CashN/A157.7635.4557.96Price / Book5.934.838.275.54Net Income-$193.51M$31.62M$3.25B$259.28M7 Day Performance-2.38%-5.28%-3.73%-4.68%1 Month Performance26.00%4.38%4.29%4.36%1 Year Performance53.21%-2.49%25.87%17.88% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix3.6107 of 5 stars$11.92+2.9%$17.33+45.4%+47.7%$1.84B$63.72M-10.37230Upcoming EarningsRGCRegencell Bioscience0.0502 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010Positive NewsRVMDRevolution Medicines4.467 of 5 stars$38.42+0.3%$68.91+79.4%-19.1%$7.13B$11.58M-9.61250News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.116 of 5 stars$10.00+0.6%$10.30+3.0%+41.1%$6.83B$7.81B8.5523,822Dividend AnnouncementTGTXTG Therapeutics4.0794 of 5 stars$37.42-1.3%$43.80+17.0%+85.0%$6.02B$329M157.96290Positive NewsUpcoming EarningsNUVLNuvalent3.2323 of 5 stars$82.46-1.1%$119.60+45.0%+2.0%$5.99BN/A-18.7840Positive NewsRYTMRhythm Pharmaceuticals3.5511 of 5 stars$88.63-0.6%$91.93+3.7%+88.5%$5.68B$130.13M-31.54140Upcoming EarningsInsider TradeCRSPCRISPR Therapeutics2.8206 of 5 stars$65.33+0.3%$71.75+9.8%+2.3%$5.62B$37.31M-14.45460Upcoming EarningsAnalyst RevisionGap DownHigh Trading VolumeAXSMAxsome Therapeutics4.8236 of 5 stars$109.68-1.8%$172.33+57.1%+19.8%$5.50B$385.69M-19.01380Positive NewsUpcoming EarningsTLXTelix PharmaceuticalsN/A$16.50+1.7%$22.33+35.4%N/A$5.49B$516.72M0.00N/AGap DownHigh Trading VolumeLNTHLantheus4.6193 of 5 stars$71.56+2.0%$131.20+83.3%-28.4%$4.86B$1.53B20.33700News CoveragePositive NewsUpcoming EarningsAnalyst Revision Related Companies and Tools Related Companies RGC Competitors RVMD Competitors GRFS Competitors TGTX Competitors NUVL Competitors RYTM Competitors CRSP Competitors AXSM Competitors TLX Competitors LNTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCUL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
